Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 356 entries
Sorted by: Best Match Show Resources per page
A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance.

International journal of psychiatry in clinical practice

MacE S, Taylor D.
PMID: 24930794
Int J Psychiatry Clin Pract. 2005;9(2):124-9. doi: 10.1080/13651500510028995.

Objective : In the United Kingdom (UK) the National Institute for Clinical Excellence (NICE) has recommended the use of atypical antipsychotics for the treatment of schizophrenia. As part of its guidance it discourages the concurrent use of typical and...

Cite
MacE S, Taylor D. A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance. Int J Psychiatry Clin Pract. 2005;9(2):124-9doi: 10.1080/13651500510028995.
MacE, S., & Taylor, D. (2005). A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance. International journal of psychiatry in clinical practice, 9(2), 124-9. https://doi.org/10.1080/13651500510028995
MacE, Shubhra, and Taylor, David. "A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance." International journal of psychiatry in clinical practice vol. 9,2 (2005): 124-9. doi: https://doi.org/10.1080/13651500510028995
MacE S, Taylor D. A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance. Int J Psychiatry Clin Pract. 2005;9(2):124-9. doi: 10.1080/13651500510028995. PMID: 24930794.
Copy Download .nbib Format: NLM
Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit.

Therapeutic advances in psychopharmacology

Gee SH, Taylor DM, Shergill SS, Flanagan R, MacCabe JH.
PMID: 28255437
Ther Adv Psychopharmacol. 2017 Feb;7(2):79-83. doi: 10.1177/2045125316677027. Epub 2016 Dec 02.

BACKGROUND: Tobacco smoke is known to affect plasma levels of some drugs, including the antipsychotic clozapine. The effects of suddenly stopping smoking on patients who take clozapine can be severe, as plasma concentrations are expected to rapidly rise, potentially...

Cite
Gee SH, Taylor DM, Shergill SS, et al. Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. Ther Adv Psychopharmacol. 2016;7(2):79-83doi: 10.1177/2045125316677027.
Gee, S. H., Taylor, D. M., Shergill, S. S., Flanagan, R., & MacCabe, J. H. (2017). Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. Therapeutic advances in psychopharmacology, 7(2), 79-83. https://doi.org/10.1177/2045125316677027
Gee, Siobhan H, et al. "Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit." Therapeutic advances in psychopharmacology vol. 7,2 (2017): 79-83. doi: https://doi.org/10.1177/2045125316677027
Gee SH, Taylor DM, Shergill SS, Flanagan R, MacCabe JH. Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. Ther Adv Psychopharmacol. 2017 Feb;7(2):79-83. doi: 10.1177/2045125316677027. Epub 2016 Dec 02. PMID: 28255437; PMCID: PMC5315231.
Copy Download .nbib Format: NLM
A Prospective Study of Adverse Drug Reactions in Patients with Bipolar Disorder in Psychiatry Outpatient Department of a Tertiary Care Hospital.

Journal of clinical and diagnostic research : JCDR

Shah A, Yadav PP, Chaudhari M, Vataliya A, Kantharia ND, Mehta R.
PMID: 28658799
J Clin Diagn Res. 2017 May;11(5):FC24-FC28. doi: 10.7860/JCDR/2017/24009.9873. Epub 2017 May 01.

INTRODUCTION: Bipolar disorder is a chronic, debilitating psychiatric disorder. Mood stabilizers and atypical antipsychotics are first line drugs for bipolar disorder. They have significant adverse effects.AIM: The study was conducted with an aim to evaluate the pattern of occurrence...

Cite
Shah A, Yadav PP, Chaudhari M, et al. A Prospective Study of Adverse Drug Reactions in Patients with Bipolar Disorder in Psychiatry Outpatient Department of a Tertiary Care Hospital. J Clin Diagn Res. 2017;11(5):FC24-FC28doi: 10.7860/JCDR/2017/24009.9873.
Shah, A., Yadav, P. P., Chaudhari, M., Vataliya, A., Kantharia, N. D., & Mehta, R. (2017). A Prospective Study of Adverse Drug Reactions in Patients with Bipolar Disorder in Psychiatry Outpatient Department of a Tertiary Care Hospital. Journal of clinical and diagnostic research : JCDR, 11(5), FC24-FC28. https://doi.org/10.7860/JCDR/2017/24009.9873
Shah, Aashal, et al. "A Prospective Study of Adverse Drug Reactions in Patients with Bipolar Disorder in Psychiatry Outpatient Department of a Tertiary Care Hospital." Journal of clinical and diagnostic research : JCDR vol. 11,5 (2017): FC24-FC28. doi: https://doi.org/10.7860/JCDR/2017/24009.9873
Shah A, Yadav PP, Chaudhari M, Vataliya A, Kantharia ND, Mehta R. A Prospective Study of Adverse Drug Reactions in Patients with Bipolar Disorder in Psychiatry Outpatient Department of a Tertiary Care Hospital. J Clin Diagn Res. 2017 May;11(5):FC24-FC28. doi: 10.7860/JCDR/2017/24009.9873. Epub 2017 May 01. PMID: 28658799; PMCID: PMC5483701.
Copy Download .nbib Format: NLM
[Study of Flexible Doses of Paliperidone ER in Pacients with Schizophrenia who Have Undergone Inefficient Treatment with other Antipsychotics].

Revista colombiana de psiquiatria

Córdoba R, Cano JF, Arango-Dávila CA, Miranda C, Holguín J, Fernández D, Márquez M, Lupo C, Gargoloff P, Petracca G, Lucchetti C.
PMID: 26573498
Rev Colomb Psiquiatr. 2012 Jun;41(2):340-56. doi: 10.1016/S0034-7450(14)60009-3. Epub 2014 May 10.

BACKGROUND: Extended-release (ER) paliperidone is an innovative atypical antipsychotic that allows minimal peak-to-through fluctuations with once-daily dosing.OBJECTIVE: To evaluate effectiveness, safety and tolerability of flexible, once-daily doses of paliperidone ER (3-12 mg/day) in patients with schizophrenia from Argentina and...

Cite
Córdoba R, Cano JF, Arango-Dávila CA, et al. Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos. [Study of Flexible Doses of Paliperidone ER in Pacients with Schizophrenia who Have Undergone Inefficient Treatment with other Antipsychotics]. Rev Colomb Psiquiatr. 2014;41(2):340-56doi: 10.1016/S0034-7450(14)60009-3.
Córdoba, R., Cano, J. F., Arango-Dávila, C. A., Miranda, C., Holguín, J., Fernández, D., Márquez, M., Lupo, C., Gargoloff, P., Petracca, G., & Lucchetti, C. (2012). Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos. [Study of Flexible Doses of Paliperidone ER in Pacients with Schizophrenia who Have Undergone Inefficient Treatment with other Antipsychotics]. Revista colombiana de psiquiatria, 41(2), 340-56. https://doi.org/10.1016/S0034-7450(14)60009-3
Córdoba, Rodrigo, et al. "Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos." [Study of Flexible Doses of Paliperidone ER in Pacients with Schizophrenia who Have Undergone Inefficient Treatment with other Antipsychotics]. Revista colombiana de psiquiatria vol. 41,2 (2012): 340-56. doi: https://doi.org/10.1016/S0034-7450(14)60009-3
Córdoba R, Cano JF, Arango-Dávila CA, Miranda C, Holguín J, Fernández D, Márquez M, Lupo C, Gargoloff P, Petracca G, Lucchetti C. Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos. [Study of Flexible Doses of Paliperidone ER in Pacients with Schizophrenia who Have Undergone Inefficient Treatment with other Antipsychotics]. Rev Colomb Psiquiatr. 2012 Jun;41(2):340-56. doi: 10.1016/S0034-7450(14)60009-3. Epub 2014 May 10. Spanish. PMID: 26573498.
Copy Download .nbib Format: NLM
Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study.

International journal of psychiatry in clinical practice

Yildiz M, Cerit C.
PMID: 24937582
Int J Psychiatry Clin Pract. 2004;8(1):41-5. doi: 10.1080/13651500310003327.

INTRODUCTION: Pharmacotherapy for schizophrenia is a dynamic process that can change over time. The goal of this study was to examine the pattern of antipsychotic drug (APD) use for patients with schizophrenia in an outpatient clinic.METHOD: We evaluated the...

Cite
Yildiz M, Cerit C. Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study. Int J Psychiatry Clin Pract. 2004;8(1):41-5doi: 10.1080/13651500310003327.
Yildiz, M., & Cerit, C. (2004). Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study. International journal of psychiatry in clinical practice, 8(1), 41-5. https://doi.org/10.1080/13651500310003327
Yildiz, Mustafa, and Cerit, Cem. "Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study." International journal of psychiatry in clinical practice vol. 8,1 (2004): 41-5. doi: https://doi.org/10.1080/13651500310003327
Yildiz M, Cerit C. Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study. Int J Psychiatry Clin Pract. 2004;8(1):41-5. doi: 10.1080/13651500310003327. PMID: 24937582.
Copy Download .nbib Format: NLM
Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update.

Chonnam medical journal

Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU.
PMID: 27689026
Chonnam Med J. 2016 Sep;52(3):159-72. doi: 10.4068/cmj.2016.52.3.159. Epub 2016 Sep 23.

Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The...

Cite
Wang SM, Han C, Lee SJ, et al. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Med J. 2016;52(3):159-72doi: 10.4068/cmj.2016.52.3.159.
Wang, S. M., Han, C., Lee, S. J., Jun, T. Y., Patkar, A. A., Masand, P. S., & Pae, C. U. (2016). Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam medical journal, 52(3), 159-72. https://doi.org/10.4068/cmj.2016.52.3.159
Wang, Sheng-Min, et al. "Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update." Chonnam medical journal vol. 52,3 (2016): 159-72. doi: https://doi.org/10.4068/cmj.2016.52.3.159
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Med J. 2016 Sep;52(3):159-72. doi: 10.4068/cmj.2016.52.3.159. Epub 2016 Sep 23. PMID: 27689026; PMCID: PMC5040765.
Copy Download .nbib Format: NLM
Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013.

Israel journal of health policy research

Ponizovsky AM, Marom E, Ben-Laish M, Barash I, Weizman A, Schwartzberg E.
PMID: 27307984
Isr J Health Policy Res. 2016 Jun 15;5:16. doi: 10.1186/s13584-016-0074-7. eCollection 2016.

BACKGROUND: Although serious mental illneses are treated with both typical and atypical antipsychotic grugs, trends in their use in psychiatric inpatient population in Israel are unrecognized. The aim of this study was to detect trends in the use of...

Cite
Ponizovsky AM, Marom E, Ben-Laish M, et al. Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. Isr J Health Policy Res. 2016;5:16doi: 10.1186/s13584-016-0074-7.
Ponizovsky, A. M., Marom, E., Ben-Laish, M., Barash, I., Weizman, A., & Schwartzberg, E. (2016). Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. Israel journal of health policy research, 516. https://doi.org/10.1186/s13584-016-0074-7
Ponizovsky, Alexander M, et al. "Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013." Israel journal of health policy research vol. 5 (2016): 16. doi: https://doi.org/10.1186/s13584-016-0074-7
Ponizovsky AM, Marom E, Ben-Laish M, Barash I, Weizman A, Schwartzberg E. Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. Isr J Health Policy Res. 2016 Jun 15;5:16. doi: 10.1186/s13584-016-0074-7. eCollection 2016. PMID: 27307984; PMCID: PMC4908675.
Copy Download .nbib Format: NLM
Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths.

Primary care companion to the Journal of clinical psychiatry

Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP.
PMID: 15156241
Prim Care Companion J Clin Psychiatry. 2003 Feb;5(1):6-14. doi: 10.4088/pcc.v05n0103.

BACKGROUND: Recently, much attention has been focused on the increased rate of metabolic syndrome componen ts among psychiatric patients, including glucose intolerance, hyperglycemia, diabetes mellitus, hyperlipidemia, hypertension, and weight gain. Various reports have identified cases of newly diagnosed diabetes...

Cite
Kabinoff GS, Toalson PA, Healey KM, et al. Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths. Prim Care Companion J Clin Psychiatry. 2003;5(1):6-14doi: 10.4088/pcc.v05n0103.
Kabinoff, G. S., Toalson, P. A., Healey, K. M., McGuire, H. C., & Hay, D. P. (2003). Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths. Primary care companion to the Journal of clinical psychiatry, 5(1), 6-14. https://doi.org/10.4088/pcc.v05n0103
Kabinoff, Gary S., et al. "Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths." Primary care companion to the Journal of clinical psychiatry vol. 5,1 (2003): 6-14. doi: https://doi.org/10.4088/pcc.v05n0103
Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP. Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths. Prim Care Companion J Clin Psychiatry. 2003 Feb;5(1):6-14. doi: 10.4088/pcc.v05n0103. PMID: 15156241; PMCID: PMC353028.
Copy Download .nbib Format: NLM
The alkaloid alstonine: a review of its pharmacological properties.

Evidence-based complementary and alternative medicine : eCAM

Elisabetsky E, Costa-Campos L.
PMID: 16550222
Evid Based Complement Alternat Med. 2006 Mar;3(1):39-48. doi: 10.1093/ecam/nek011. Epub 2006 Jan 16.

Indole compounds, related to the metabolism of tryptophan, constitute an extensive family, and are found in bacteria, plants and animals. Indolic compounds possess significant and complex physiological roles, and especially indole alkaloids have historically constituted a class of major...

Cite
Elisabetsky E, Costa-Campos L. The alkaloid alstonine: a review of its pharmacological properties. Evid Based Complement Alternat Med. 2006;3(1):39-48doi: 10.1093/ecam/nek011.
Elisabetsky, E., & Costa-Campos, L. (2006). The alkaloid alstonine: a review of its pharmacological properties. Evidence-based complementary and alternative medicine : eCAM, 3(1), 39-48. https://doi.org/10.1093/ecam/nek011
Elisabetsky, E, and Costa-Campos, L. "The alkaloid alstonine: a review of its pharmacological properties." Evidence-based complementary and alternative medicine : eCAM vol. 3,1 (2006): 39-48. doi: https://doi.org/10.1093/ecam/nek011
Elisabetsky E, Costa-Campos L. The alkaloid alstonine: a review of its pharmacological properties. Evid Based Complement Alternat Med. 2006 Mar;3(1):39-48. doi: 10.1093/ecam/nek011. Epub 2006 Jan 16. PMID: 16550222; PMCID: PMC1375234.
Copy Download .nbib Format: NLM
Recognizing and managing antipsychotic drug treatment side effects in the elderly.

Primary care companion to the Journal of clinical psychiatry

Saltz BL, Robinson DG, Woerner MG.
PMID: 16001096
Prim Care Companion J Clin Psychiatry. 2004;6:14-9.

Although atypical antipsychotics differ from conventional antipsychotics in their decreased ability to cause reversible drug-induced movement disorders/motor side effects such as dystonia, drug-induced parkinsonism, and akathisia and potentially persistent drug-induced movement disorders/motor side effects such as tardive dyskinesia, no...

Cite
Saltz BL, Robinson DG, Woerner MG. Recognizing and managing antipsychotic drug treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry. 2004;6:14-9
Saltz, B. L., Robinson, D. G., & Woerner, M. G. (2004). Recognizing and managing antipsychotic drug treatment side effects in the elderly. Primary care companion to the Journal of clinical psychiatry, 614-9.
Saltz, Bruce L, et al. "Recognizing and managing antipsychotic drug treatment side effects in the elderly." Primary care companion to the Journal of clinical psychiatry vol. 6 (2004): 14-9.
Saltz BL, Robinson DG, Woerner MG. Recognizing and managing antipsychotic drug treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry. 2004;6:14-9. PMID: 16001096; PMCID: PMC487007.
Copy Download .nbib Format: NLM
QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.

Annals of general psychiatry

Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM.
PMID: 15845138
Ann Gen Psychiatry. 2005 Jan 25;4(1):1. doi: 10.1186/1744-859X-4-1.

BACKGROUND: Several antipsychotic agents are known to prolong the QT interval in a dose dependent manner. Corrected QT interval (QTc) exceeding a threshold value of 450 ms may be associated with an increased risk of life threatening arrhythmias. Antipsychotic...

Cite
Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005;4(1):1doi: 10.1186/1744-859X-4-1.
Sala, M., Vicentini, A., Brambilla, P., Montomoli, C., Jogia, J. R., Caverzasi, E., Bonzano, A., Piccinelli, M., Barale, F., & De Ferrari, G. M. (2005). QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Annals of general psychiatry, 4(1), 1. https://doi.org/10.1186/1744-859X-4-1
Sala, Michela, et al. "QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy." Annals of general psychiatry vol. 4,1 (2005): 1. doi: https://doi.org/10.1186/1744-859X-4-1
Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005 Jan 25;4(1):1. doi: 10.1186/1744-859X-4-1. PMID: 15845138; PMCID: PMC1088007.
Copy Download .nbib Format: NLM
Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Neuropsychiatric disease and treatment

Chue P.
PMID: 19300536
Neuropsychiatr Dis Treat. 2007 Feb;3(1):13-39. doi: 10.2147/nedt.2007.3.1.13.

OBJECTIVE: To review the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone.METHODS: Studies published between January 2000 and October 2006 evaluating the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone were reviewed, as identified from literature searches using Medline...

Cite
Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat. 2007;3(1):13-39doi: 10.2147/nedt.2007.3.1.13.
Chue, P. (2007). Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatric disease and treatment, 3(1), 13-39. https://doi.org/10.2147/nedt.2007.3.1.13
Chue, Pierre. "Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic." Neuropsychiatric disease and treatment vol. 3,1 (2007): 13-39. doi: https://doi.org/10.2147/nedt.2007.3.1.13
Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat. 2007 Feb;3(1):13-39. doi: 10.2147/nedt.2007.3.1.13. PMID: 19300536; PMCID: PMC2654523.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 356 entries